Matinas BioPharma Hldgs Analyst Ratings
Matinas BioPharma Hldgs Analyst Ratings
While ratings are subjective and will change, the latest Matinas BioPharma Hldgs (MTNB) rating was a reiterated with a price target of $0.00 to $3.00. The current price Matinas BioPharma Hldgs (MTNB) is trading at is $0.59, which is within the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 01/31/2023 | 412.38% | HC Wainwright & Co. | → $3 | Reiterates | → Buy |
| 08/13/2020 | 497.78% | Aegis Capital | $3.25 → $3.5 | Maintains | Buy |
| 01/27/2020 | 412.38% | Piper Sandler | → $3 | Initiates Coverage On | → Overweight |
| 01/24/2020 | 412.38% | SunTrust Robinson Humphrey | → $3 | Initiates Coverage On | → Buy |
| 06/26/2019 | 583.18% | HC Wainwright & Co. | → $4 | Initiates Coverage On | → Buy |
| 05/17/2019 | 753.97% | BTIG | → $5 | Initiates Coverage On | → Buy |
| 02/11/2019 | — | Roth Capital | Initiates Coverage On | → Buy | |
| 11/13/2018 | 753.97% | Maxim Group | $2 → $5 | Maintains | Buy |
| 08/13/2018 | 241.59% | Maxim Group | $3 → $2 | Maintains | Buy |
| 07/10/2018 | 412.38% | Maxim Group | $4 → $3 | Maintains | Buy |
| 日期 | 上/下行 | 分析師公司 | 价格目標變更 | 評級變更 | 上一頁/目前評分 |
|---|---|---|---|---|---|
| 01/31/2023 | 412.38% | HC 溫賴特 & 有限公司. | → 3 美元 | 重申 | → 購買 |
| 08/13/2020 | 497.78% | 神盾資本 | 三點二五 → 3.5 美元 | 維護 | 購買 |
| 01/27/2020 | 412.38% | 吹笛者桑德勒 | → 3 美元 | 啟動覆蓋範圍 | → 超重 |
| 01/24/2020 | 412.38% | 太陽信託羅賓遜·漢弗萊 | → 3 美元 | 啟動覆蓋範圍 | → 購買 |
| 06/26/2019 | 583.18% | HC 溫賴特 & 有限公司. | → 4 美元 | 啟動覆蓋範圍 | → 購買 |
| 05/17/2019 | 753.97% | BTIG | → 5 美元 | 啟動覆蓋範圍 | → 購買 |
| 02/11/2019 | — | 羅斯資本 | 啟動覆蓋範圍 | → 購買 | |
| 11/13/2018 | 753.97% | 美心集團 | 2 美元 → 5 美元 | 維護 | 購買 |
| 2018 年 8 月 13 日 | 241.59% | 美心集團 | 3 美元 → 2 美元 | 維護 | 購買 |
| 2018 年 7 月 10 日 | 412.38% | 美心集團 | 4 美元 → 3 美元 | 維護 | 購買 |
What is the target price for Matinas BioPharma Hldgs (MTNB)?
美蒂納斯生物製藥控股 (MTNB) 的目標價格是多少？
The latest price target for Matinas BioPharma Hldgs (AMEX: MTNB) was reported by HC Wainwright & Co. on January 31, 2023. The analyst firm set a price target for $3.00 expecting MTNB to rise to within 12 months (a possible 412.38% upside). 1 analyst firms have reported ratings in the last year.
韋賴特有限公司於 2023 年 1 月 31 日報導了馬蒂納斯生物製藥控股有限公司（AMEX 代碼：MTNB）的最新目標價格。該分析師公司設定了 3.00 美元的價格目標，預計 MTNB 將在 12 個月內上升（可能是 412.38％ 的上漲）。1 家分析師公司在去年報告了評級。
What is the most recent analyst rating for Matinas BioPharma Hldgs (MTNB)?
美蒂納斯生物製藥控股 (MTNB) 的最新分析師評級為何？
The latest analyst rating for Matinas BioPharma Hldgs (AMEX: MTNB) was provided by HC Wainwright & Co., and Matinas BioPharma Hldgs reiterated their buy rating.
馬蒂納斯生物製藥控股有限公司（AMEX：MTNB）的最新分析師評級由 HC 溫賴特公司提供，美蒂納斯生物製藥控股重申其購買評級。
When is the next analyst rating going to be posted or updated for Matinas BioPharma Hldgs (MTNB)?
美蒂納斯生物製藥控股 (MTNB) 的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Matinas BioPharma Hldgs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Matinas BioPharma Hldgs was filed on January 31, 2023 so you should expect the next rating to be made available sometime around January 31, 2024.
分析師在做廣泛的研究後到達股票評級，其中包括通過公共財務報表，與 Matinas BioHharma Hldgs 的高管和客戶交談，以及聽取盈利電話會議。大多數分析師每三個月這樣做一次，因此您應該每年每家公司獲得 4 個評級。Matinas 生物製藥控股的最後評級於 2023 年 1 月 31 日提交，因此您應該期望下一個評級將在 2024 年 1 月 31 日左右的某個時間提供。
Is the Analyst Rating Matinas BioPharma Hldgs (MTNB) correct?
分析師評級馬蒂納斯生物製藥控股 (MTNB) 是否正確？
While ratings are subjective and will change, the latest Matinas BioPharma Hldgs (MTNB) rating was a reiterated with a price target of $0.00 to $3.00. The current price Matinas BioPharma Hldgs (MTNB) is trading at is $0.59, which is within the analyst's predicted range.
儘管評級是主觀的並且會發生變化，但最新的馬蒂納斯生物製藥控股（MTNB）評級重申，目標價格為 0.00 美元至 3.00 美元。目前的價格馬蒂納斯生物製藥控股（MTNB）的交易價格為 $0.59，這是分析師的預測範圍內。
譯文內容由第三人軟體翻譯。
